Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 25

recruiting
3 968
countries
28
conditions
2 103

344 trials match your criteria

Non-small cell lung cancer

Not recruiting

Study of Sacituzumab Govitecan, Pembrolizumab, and a Platinum Drug Combination for Advanced Non-Small Cell Lung Cancer Patients Without Genomic Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

HER2 positive breast cancer

Not recruiting

Study on Trastuzumab and Pertuzumab for Patients with HER2-Positive Breast Cancer Using a Response-Adapted Strategy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Diffuse large B-cell lymphoma+1

Not recruiting

Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Furmonertinib vs. Platinum-Based Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Not recruiting

Study of MK-7684A with Chemoradiotherapy Compared to Chemoradiotherapy with Durvalumab for Patients with Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Endometrial cancer

Not recruiting

Study on the Effectiveness of Biomarker Staging Compared to Conventional Staging in Women with Early-Stage Endometrial Cancer Using Paclitaxel and Carboplatin

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing MK-7684A with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of BLU-222 Alone and with Drug Combination for Patients with Advanced Solid Tumors, Including Breast and Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Blu-222

Endometrial cancer

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Bladder transitional cell carcinoma+2

Not recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Not recruiting

Study of Immunotherapy Combinations Including Zimberelimab for Patients With Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.